STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model

Byung Hak Kim, Haeri Lee, Cheol Gyu Park, Ae Jin Jeong, Song Hee Lee, Kum Hee Noh, Jong Bae Park, Chung Gi Lee, Sun Ha Paek, Hyunggee Kim, Sang Kyu Ye

Research output: Contribution to journalArticlepeer-review

Abstract

Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for cancer therapy. We recently identified ODZ10117 as a small molecule inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted cancer therapy. Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells. In addition, ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs). Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells. Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3.

Original languageEnglish
JournalCells
Volume9
Issue number3
DOIs
Publication statusPublished - 2020 Mar 15

Keywords

  • ODZ10117
  • STAT3
  • glioblastoma
  • glioma stem cell (GSC)
  • targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model'. Together they form a unique fingerprint.

Cite this